{
    "id": 2756,
    "fullName": "ERBB3 V104M",
    "impact": "missense",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "ERBB3 (HER3) V104M lies within the extracellular domain of the Erbb3 (Her3) protein (UniProt.org). V104M may confer a gain of Erbb3 (Her3) protein function, resulting in phosphorylation of Akt and Erk, as well as oncogenic transformation of Erbb2 (Her2) expressing cells (PMID: 23680147), however in another study, V104M results in similar cell proliferation and viability levels as wild-type Erbb3 (Her3) (PMID: 29533785), and therefore, its effect on Erbb3 (Her3) protein function is unknown (PubMed, Feb 2020).",
            "references": [
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                },
                {
                    "id": 11238,
                    "pubMedId": 29533785,
                    "title": "Systematic Functional Annotation of Somatic Mutations in Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29533785"
                },
                {
                    "id": 323,
                    "pubMedId": 23680147,
                    "title": "Oncogenic ERBB3 mutations in human cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23680147"
                },
                {
                    "id": 285,
                    "pubMedId": null,
                    "title": null,
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 2065,
        "geneSymbol": "ERBB3",
        "terms": [
            "ERBB3",
            "c-erbB-3",
            "c-erbB3",
            "ErbB-3",
            "erbB3-S",
            "FERLK",
            "HER3",
            "LCCS2",
            "MDA-BF-1",
            "p180-ErbB3",
            "p45-sErbB3",
            "p85-sErbB3"
        ]
    },
    "variant": "V104M",
    "createDate": "12/17/2014",
    "updateDate": "02/05/2020",
    "referenceTranscriptCoordinates": {
        "id": 123519,
        "transcript": "NM_001982",
        "gDna": "chr12:g.56085070G>A",
        "cDna": "c.310G>A",
        "protein": "p.V104M",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 2114,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Tykerb (lapatinib) inhibited proliferation and colony formation in transformed cell lines expressing ERBB3 (HER3) V104M (PMID: 23680147).",
            "molecularProfile": {
                "id": 2574,
                "profileName": "ERBB3 V104M"
            },
            "therapy": {
                "id": 787,
                "therapyName": "Lapatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 323,
                    "pubMedId": 23680147,
                    "title": "Oncogenic ERBB3 mutations in human cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23680147"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11945,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Pictilisib (GDC-0941) inhibited cell proliferation in transformed cell lines expressing ERBB3 (HER3) V104M in culture (PMID: 23680147).",
            "molecularProfile": {
                "id": 2574,
                "profileName": "ERBB3 V104M"
            },
            "therapy": {
                "id": 749,
                "therapyName": "Pictilisib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 323,
                    "pubMedId": 23680147,
                    "title": "Oncogenic ERBB3 mutations in human cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23680147"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5944,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II clinical trial, a patient with ERBB3 V104M mutant urothelial carcinoma had improved progression free survival when treated with Gilotrif (afatinib), and median PFS was 6.6 months for patients with ERBB2 or ERBB3 alterations relative to 1.4 months for patients lacking alterations (PMID: 27044931).",
            "molecularProfile": {
                "id": 2574,
                "profileName": "ERBB3 V104M"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 11054,
                "name": "urinary bladder cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5203,
                    "pubMedId": 27044931,
                    "title": "Afatinib Activity in Platinum-Refractory Metastatic Urothelial Carcinoma in Patients With ERBB Alterations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27044931"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 11940,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Perjeta (pertuzumab) inhibited cell proliferation in transformed cell lines expressing ERBB3 (HER3) V104M in culture (PMID: 23680147).",
            "molecularProfile": {
                "id": 2574,
                "profileName": "ERBB3 V104M"
            },
            "therapy": {
                "id": 856,
                "therapyName": "Pertuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 323,
                    "pubMedId": 23680147,
                    "title": "Oncogenic ERBB3 mutations in human cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23680147"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11941,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Herceptin (trastuzumab) inhibited cell proliferation in transformed cell lines expressing ERBB3 (HER3) V104M in culture (PMID: 23680147).",
            "molecularProfile": {
                "id": 2574,
                "profileName": "ERBB3 V104M"
            },
            "therapy": {
                "id": 947,
                "therapyName": "Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 323,
                    "pubMedId": 23680147,
                    "title": "Oncogenic ERBB3 mutations in human cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23680147"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 2574,
            "profileName": "ERBB3 V104M",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 123519,
            "transcript": "NM_001982",
            "gDna": "chr12:g.56085070G>A",
            "cDna": "c.310G>A",
            "protein": "p.V104M",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 123520,
            "transcript": "NM_001005915",
            "gDna": "chr12:g.56085070G>A",
            "cDna": "c.310G>A",
            "protein": "p.V104M",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}